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Background: Pharmacokinetics (PK) and pharmacodynamics of efavirenz and its 8-hydroxy metabolite (8-OH-
efavirenz) have not been robustly evaluated in older HIV-infected persons.
Objectives: We investigated relationships between neuropsychological (NP) performance and efavirenz and
8-OH-efavirenz PK in HIV-infected individuals .50 years of age.
Methods: A cross-sectional study of HIV-infected adults on an efavirenz-containing regimen. The 12 and 18 h
post-dose plasma efavirenz and 8-OH-efavirenz were quantified. CYP2B6 polymorphisms were investigated.
Participants underwent neuropsychological tests; surveys were used for depression, sleep quality and anxiety.
We investigated potential correlations of efavirenz and 8-OH-efavirenz plasma concentrations with NP perform-
ance, sleep, depression, anxiety and CYP2B6 polymorphisms.
Results: Thirty participants (24 men and 6 women) with mean age 57 years (range 50–68). Plasma efavirenz
concentrations did not correlate with NP performance; however, higher plasma 8-OH-efavirenz correlated with
better learning (P¼0.002), language (P¼0.002) and total NP z-scores (P¼0.003). No correlation was seen for
efavirenz or 8-OH-efavirenz with sleep, anxiety or depression. Median 12 and 18 h efavirenz plasma concentra-
tions were 1967 ng/mL (IQR 1476–2394) and 1676 ng/mL (IQR 1120–2062), respectively. Median 12 and 18 h
8-OH-efavirenz plasma concentrations were 378 ng/mL (IQR 223–589) and 384 ng/mL (IQR 216–621), respect-
ively. CYP2B6 G516T was associated with significantly higher plasma efavirenz at 12 and 18 h (P¼0.02) but not
worse NP function.
Conclusions: Better neurocognitive functioning was associated with higher 8-OH-efavirenz but not efavirenz
plasma concentrations. No correlation was observed with sleep or depression. These findings point to a need
for greater understanding of the metabolic profile of efavirenz and 8-OH-efavirenz in plasma and the CNS and
relationships with antiviral effect and neurotoxicity.
Introduction
The US CDC estimates that up to 15% of newly diagnosed cases of
HIV infection are among people aged ≥50 years. By 2016, more
than one-half of all HIV-infected individuals in the USA will be
aged .50 years, not only from new cases but the greatly
increased lifespan attributed to ART.1 Assessments of antiretro-
viral pharmacokinetics (PK) in older HIV-infected patients are
sparse and there are no specific dosing guidelines for older
patients in contrast to the general geriatric population.2 Studies
in older populations demonstrate decrements in liver metabolism
and renal clearance, which may require dosage adjustments
for drugs eliminated by the kidney. Additionally, decreased
bioavailability due to changes in drug transporters alter the PK
of many drugs in older populations.3,4 In a relevant study of
older HIV-infected patients, trough lopinavir concentrations
from 44 subjects showed that older age was associated with
higher lopinavir concentrations.3 In another study of 51 patients
receiving darunavir, a univariate analysis determined that every
10 years of age lowered the clearance of darunavir by 19%.5
Importantly, efavirenz has been sparsely evaluated in older
patients,6 even though this is one of the most commonly pre-
scribed antiretroviral agents.7,8
CNS side effects associated with efavirenz are common and for
this reason it is recommended that the drug be taken at bedtime.9
Neuropsychological (NP) performance and symptoms associated
# The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
For Permissions, please e-mail: journals.permissions@oup.com
doi:10.1093/jac/dkw403
J Antimicrob Chemother 2017; : 200–20472
Advance Access publication 21 September 2016
200
with efavirenz use were carefully evaluated in the ACTG study
5097. In this study, individuals on efavirenz experienced an
increased rate of bad dreams and had an increased rate of neuro-
logical symptoms that correlated with plasma concentrations of
efavirenz, but only during the first week of treatment. No differ-
ences were seen in depression or anxiety between those on efavir-
enz and those on other regimens. Six percent of patients
discontinued efavirenz as a result of neuropsychiatric side
effects.10 Pharmacogenetics (PG) may also play an important
role in efavirenz exposure in the older population as previous stud-
ies have shown correlations between both efavirenz concentra-
tions and CNS adverse effects and CYP2B6 polymorphisms in
adults.11,12
Efavirenz is primarily metabolized in the liver. Clearance of efa-
virenz occurs predominantly via CYP2B6 to an 8-OH-efavirenz
metabolite.13–16 Additionally, there is a subsequent pathway via
CYP2A6 to a 7-OH-efavirenz metabolite.13–15 The 8-OH-efavirenz
metabolitewas found to induce direct neuronal toxicity and death
via increased Ca2+ influx in vitro.17 CYP2B6 polymorphisms have
been associated with higher plasma concentrations of efavirenz.
Subsequently, CYP2B6 polymorphisms have been observed in
patients with increased frequency of efavirenz-related side effects
and are associated with drug discontinuation.11,12 In addition to
CYP2B6, early treatment discontinuation of efavirenz was also
associated with a polymorphism in the constitutive androstane
receptor.16
The aim of this study was to investigate steady-state PK of efa-
virenz, in older HIV-infected patients, to correlate efavirenz and
8-OH-efavirenz drug exposure with NP performance and to
explore the role of CYP2B6 polymorphisms in efavirenz metabol-
ism in patients .50 years of age.
Patients and methods
A cross-sectional study was conducted at the University of Nebraska
Medical Center. Entry criteria were a diagnosis of HIV disease, .50 years
of age and on an efavirenz-containing regimen for .12 weeks.
Participants were required to be able to provide written informed consent
and to complete the questionnaires in English, as not all of the NP screens
and questionnaires have been validated in other languages. Exclusion cri-
teria were recent intercurrent acute infection, active psychiatric illness,
active neurological disease, current delirium or intoxication and active
drug or alcohol abuse.
Participant medical records were accessed to obtain demographic and
medical history data, hepatitis C virus (HCV) status, CD4+ T cell count and
HIV viral loadwhen availablewithin≤3 months of study entry. Participants
underwent a validated NP battery to evaluate multiple domains most
affected by HIV disease including executive function, motor skills, verbal
learning, memory and speed of processing. The specific instruments
used were: the Wide Range Achievement Test 4 (WRAT-4) Reading Test;
Timed Gait; Hopkins Verbal Learning Test—Revised; Trailmaking A and B;
Grooved Pegboard; the Wechsler Adult Intelligence Scale (WAIS-3) Digit
Symbol; Verbal or Letter Fluency; and the Stroop Interference Task.
Normative standards were used, which are corrected for age, education,
sex and ethnicity as appropriate. The validated questionnaires adminis-
tered were the Center for Epidemiologic Studies Depression Scale
(CES-D) to assess for depression and the Pittsburgh Sleep Quality Index
to assess for sleep.
Participants were asked to record the time of efavirenz dosing the night
before and plasma samples were collected 12 and 18 h post-dose for
measurement of efavirenz and 8-OH-efavirenz concentrations. The
sampling schedule was chosen as efavirenz is typically dosed daily in
the evening and PK/pharmacodynamic relationships have been estab-
lished for mid-dosing interval efavirenz concentrations, including risk of
both CNS side effects and virological failure.18 In addition, whole blood
was collected for PG analysis. Efavirenz and its 8-OH metabolite concen-
trations were quantified via LC-MS/MS19,20 in the Antiviral Pharmacology
Laboratory of the University of Nebraska Medical Center.
PG analyses were performed at the University of Liverpool. Genotyping
was conducted by real-time PCR-based allelic discrimination using stand-
ard methodology.16 The genes of interest include genes coding for pro-
teins involved in phase I metabolism (CYP2B6, CYP3A4, CYP2D6 and
CYP2A6), phase II metabolism (UGT2B7) and factors of transcriptional
regulation of drug disposition (PXR and CAR).
Table 1. Patient characteristics, median 12 and 18 h efavirenz and
8-OH-efavirenz concentrations and correlations between efavirenz and
8-OH-efavirenz concentrations and neuropsychological tests
Variable Value Range (IQR)
Median age 57 50–68
Median time on
ART, years
11.25 1–22.8 (10.92)
Median CD4
cells/mm3
657 145–2062 (463)
Nadir CD4
cells/mm3
259 7–769 (342)
HIV RNA
,20 copies/mL
30a —
Hepatitis C
antibody
3b —
PK determination
(median),
ng/mL
12 h EFV 1967 IQR 1476–2394
18 h EFV 1676 IQR 1120–2062
12 h 8-OH-EFV 378 IQR 223–589
18 h 8-OH-EFV 384 IQR 216–621
Efavirenz 8-OH-efavirenz
NP test 12 h post 18 h post 12 h post 18 h post P valuec
Total z 0.04 0.09 0.38 0.52 0.003
Motor 0.13 0.15 0.20 0.37 0.044
Learning 0.1 0.11 0.52 0.61 0.002
Memory 0.05 0.13 0.27 0.2 0.24
Language 0.05 0.08 0.5 0.53 0.002
Executive 20.03 20.05 0.16 0.29 0.12
Speed 0.11 20.02 0.31 0.42 0.02
Fluency 0.24 0.24 0.14 0.24 0.2
P values considered significant if ,0.01. PK, pharmacokinetics; EFV,
efavirenz; 8-OH-EFV, 8-hydroxy efavirenz.
aTwenty-six participants had HIV RNA ,20 copies/mL and four had HIV
RNA ,100 copies/mL, but all four had HIV RNA ,20 copies/mL on subse-
quent measurements.
bThree participants had positive HCVantibodies, all had undetectable HCV
viraemia at the time of study. Two participants had been previously trea-
ted for HCV and one had spontaneously cleared viraemia.
cAdjusted with Bonferroni correction.
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Ethics
The study was approved by the University of Nebraska Institutional Review
Board (IRB no. 209-13-FB). All study patients provided signed informed
consent.
Statistical analysis
Participant characteristics and outcomes were descriptively summarized
using medians, range and proportions. The median and IQR were used
to report drug and metabolite concentrations. Raw NP scores were stan-
dardized to z-scores (NPZ) in order to adjust for age and education.
Pearson’s correlation test was used to examine correlations of plasma
efavirenz and 8-OH-efavirenz concentrations with NP test results.
Bonferroni correction was applied for tests with multiple comparisons. A
P value ,0.01 (Bonferroni correction) was used to define significance for
correlations between efavirenz and 8-OH-efavirenz and NP test results.
Results
Thirty participants were recruited. There were 24 men and 6
women; 22 white and 8 black.
Patient characteristics and median 12 and 18 h efavirenz and
8-OH-efavirenz concentrations are summarized in Table 1. When
looking at NP performance, 21 participants scored less than 21
in two domains and 12 overall had composite NPZ scores below
21. Plasma concentrations of efavirenz did not correlate with
NP performance (Table 1 and Figure 1). Conversely, higher
8-OH-efavirenz plasma concentrations at 12 and 18 h correlated
with better learning (P¼0.002), language (P¼0.002) and total NPZ
scores (P¼0.003) (Table 1 and Figure 1).
Twenty-one participants had poor sleep quality (score.5 on
Pittsburgh Sleep Quality Index) with amedian score of 7.5 (range
1–16; IQR¼6). The median CES-D score was 15. Fourteen parti-
cipants had increased risk of clinical depression (CES-D score
.16). There was no significant difference in the median 12
and 18 h efavirenz or 8-OH-efavirenz concentrations between
participants with or without depression or between those with
poor or better sleep scores. Neither higher or lower efavirenz
nor 8-OH-efavirenz plasma concentrations correlated with
sleep disturbance, anxiety or depression. No correlation was
seen between 8-OH-efavirenz concentrations and age of
participants.
Three participants were homozygous for the CYP2B6 G516T
polymorphism; two of the three had elevated 12 h (5634 and
8962 ng/mL) and 18 h (5944 and 9194 ng/mL) plasma efavir-
enz concentrations while the remaining participant had efavir-
enz concentrations within normal range (12 h¼2562 and
18 h¼2114 ng/mL).
Presence of the CYP2B6 G516T polymorphism was associated
with significantly higher concentrations of efavirenz at 12 and
18 h (P¼0.02), but did not correlate with worse NP function.
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Figure 1. Correlation of efavirenz (EFV) and 8-OH-EFV concentrations and neuropsychological performance. Not all comparisons are included.
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Discussion
The findings of our studywere unexpected. As the 8-OHmetabolite
of efavirenz has been shown to be neurotoxic in vitro, we expected
worse NP function in patients with higher 8-OH-efavirenz concen-
trations. In contrast, we found that better neurocognitive function
was associated with both higher 12 and 18 h 8-OH-efavirenz
plasma concentrations. These findings may be explained by previ-
ous clinical data that have correlated higher efavirenz concentra-
tions with greater risk of CNS side effects.18 Patients with faster
clearance of plasma efavirenz could potentially have higher
8-OH-efavirenz concentrations and lower efavirenz concentrations
by nature of clearing efavirenz more quickly, thus leading to lower
efavirenz exposure and ultimately less severe CNS adverse effects.
Winston et al.21 found a positive correlation between increased fre-
quency of efavirenz-related side effects and CSF 8-OH-efavirenz
exposure. Interestingly, there was no correlation between plasma
efavirenz or 8-OH-efavirenz and CSF 8-OH-efavirenz concentra-
tions and the authors have proposed that higher exposure to
8-OH-efavirenz in CSF may be related to saturation effects or
local efavirenz metabolic pathways in the blood–brain barrier.21
In contrast to the findings by Johnson et al.,22 where abnormal
NP performance was found in a group of HIV-negative partici-
pants after a single dose of efavirenz, no correlation was found
between higher or lower efavirenz concentrations and NP per-
formance in our cohort. Although this can be explained by differ-
ences between the population studied by Johnson et al.22 and the
patients in our study, who could have self-selected for tolerance
of efavirenz CNS effects as they all came into the studywith a long
history of efavirenz treatment. We were not able to replicate the
findings by Gallego et al.,23 where higher efavirenz plasma con-
centrations were seen in those with insomnia or reduced sleep
efficiency, but we must note that mean efavirenz concentrations
were higher than in our study. NP performance in our cohort
showed a negatively skewed curve; moreover, two-thirds had
NPZ scores of less than 21 in two or more domains, which
would classify them as being impaired. If we consider total NPZ
scores, 12 participants would be classified as impaired.24 This is
consistent with NP performance of other chronically HIV-infected
patients.6
Limitations of this study include that it was a single-centre
study with a small sample size. Moreover, the cohort used in our
study had long-standing HIV disease and long history of exposure
to efavirenz-containing regimens. These attributes may have ren-
dered our cohort less likely to report NP issues related to efavirenz
use. Additionally, we did not have a control group or CSF samples
for efavirenz or 8-OH-efavirenz determination.
Although the PK of 8-OH-efavirenz has not been extensively stud-
ied in vivo, it is possible that this metabolite does not cross the
blood–brain barrier as effectively as efavirenz. 8-OH-efavirenz
concentrations in the CSF would be dependent on both
8-OH-efavirenz penetration into the CSF as well as local metabolism
of the parent drug in CSF. If this was true, we would expect to find
higher CSF concentrations of 8-OH-efavirenz in those with higher
concentrations of efavirenz in the CSF only. This hypothesis may
in part explain better function related to higher plasma
8-OH-efavirenz, as less efavirenz would be transported in the CSF
and the 8-OHmetabolitewould be compartmentalized in plasma.25
These findings point to a need for greater understanding of the
metabolic profile of efavirenz and 8-OH-efavirenz in plasma and
the CNS and relationships with antiviral effect and potential
neurotoxicity.
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